{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:37:21Z","timestamp":1790858241313,"version":"4.1.0"},"reference-count":140,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T00:00:00Z","timestamp":1290470400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mount Sinai J Medicine"],"published-print":{"date-parts":[[2010,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With an understanding of the molecular changes that accompany cell transformation, cancer drug discovery has undergone a dramatic change in the past few years. Whereas most of the emphasis in the past has been placed on developing drugs that induce cell death based on mechanisms that do not discriminate between normal and tumor cells, recent strategies have emphasized targeting specific mechanisms that have gone awry in tumor cells. However, the identification of cancer\u2010associated mutations in oncogenes and their amplification in tumors has suggested that inhibitors against such proteins might represent attractive substrates for targeted therapy. In the clinic, the success of imatinib (Gleevec\u00ae, STI571) and trastuzumab (Herceptin\u00ae), both firsts of their kind, spurred further development of new, second\u2010generation drugs that target kinases in cancer. This review highlights a few important examples each of these types of therapies, along with some newer agents that are in various stages of development. Second\u2010generation kinase inhibitors aimed at overriding emerging resistance to these therapies are also discussed.<jats:bold><jats:italic>Mt Sinai J Med 77:573\u2013586, 2010<\/jats:italic><\/jats:bold>\u00a9<jats:italic>2010 Mount Sinai School of Medicine<\/jats:italic><\/jats:p>","DOI":"10.1002\/msj.20220","type":"journal-article","created":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T10:17:10Z","timestamp":1290593830000},"page":"573-586","source":"Crossref","is-referenced-by-count":33,"title":["Targeted Inhibition of Kinases in Cancer Therapy"],"prefix":"10.1002","volume":"77","author":[{"given":"Stacey J.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Premkumar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,23]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"1497","article-title":"A minute chromosome in human granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/315758a0"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206942"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402951"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70379-0"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2010.01.056"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702654104"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3691"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.3.1070"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3498"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402741"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.690"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1484"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn188"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-040022"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403898"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604716104"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1271"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602402103"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2007.06.001"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk150"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404609"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3207"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2008.06.002"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6858"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1152403"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2760"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1731"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2050"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0170"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-096396"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409770102"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.9128"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30890"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.10.001"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1932"},{"key":"e_1_2_8_49_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3365.3365","article-title":"Molecular interactions between the highly selective pan\u2010Bcr\u2010Abl inhibitor, AMN107, and the tyrosine kinase domain of Abl","volume":"106","author":"Manley PW","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2601"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5015"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800587105"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2324"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0117"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08675"},{"key":"e_1_2_8_57_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1128\/jvi.36.3.676-683.1980","article-title":"Avian erythroblastosis virus produces two mRNAs","volume":"36","author":"Anderson SM","year":"1980","journal-title":"J Virol"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(82)90383-X"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(83)90153-8"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3500513"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.20.7159"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2003.11.005"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90042-6"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50028"},{"key":"e_1_2_8_65_2","first-page":"5749","article-title":"ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy","volume":"62","author":"Wakeling AE","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600299"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.10239"},{"key":"e_1_2_8_68_2","first-page":"2958","article-title":"Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor","volume":"7","author":"Ciardiello F","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_69_2","first-page":"2554","article-title":"ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase","volume":"62","author":"Hirata A","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0646"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11748-007-0193-8"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405220101"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210383"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1846"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0555"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh217"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.465.3.4"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20550"},{"key":"e_1_2_8_81_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0022-3565(24)35162-6","article-title":"Inhibition of epidermal growth factor receptor\u2010associated tyrosine phosphorylation in human carcinomas with CP\u2010358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice","volume":"291","author":"Pollack VA","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_82_2","first-page":"3335","article-title":"Mutant epidermal growth factor receptor up\u2010regulates molecular effectors of tumor invasion","volume":"62","author":"Lal A","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm222"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-7-840"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044238"},{"key":"e_1_2_8_86_2","first-page":"225","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"3","author":"Pao W","year":"2005","journal-title":"PloS Med"},{"key":"e_1_2_8_87_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1671"},{"key":"e_1_2_8_88_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4625"},{"key":"e_1_2_8_89_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709662105"},{"key":"e_1_2_8_90_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0714"},{"key":"e_1_2_8_91_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1570"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020017"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1141478"},{"key":"e_1_2_8_94_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710370104"},{"key":"e_1_2_8_95_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28656"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1684"},{"key":"e_1_2_8_97_2","first-page":"2609","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF\u2010binding proteins","volume":"118","author":"Guix M","year":"2008","journal-title":"J Clin Invest"},{"key":"e_1_2_8_98_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0132"},{"key":"e_1_2_8_99_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2868"},{"key":"e_1_2_8_100_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502860102"},{"key":"e_1_2_8_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.06.005"},{"key":"e_1_2_8_102_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-2387"},{"key":"e_1_2_8_103_2","doi-asserted-by":"publisher","DOI":"10.1038\/312513a0"},{"key":"e_1_2_8_104_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2992089"},{"key":"e_1_2_8_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90592-7"},{"key":"e_1_2_8_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90331-0"},{"key":"e_1_2_8_107_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_8_108_2","first-page":"1238","article-title":"Correlation of c\u2010erbB\u20102 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading","volume":"48","author":"Berger MS","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2470152"},{"key":"e_1_2_8_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.01.009"},{"issue":"4","key":"e_1_2_8_111_2","first-page":"60","article-title":"Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)","volume":"26","author":"Sliwkowski MX","year":"1999","journal-title":"Semin Oncol"},{"key":"e_1_2_8_112_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0090075"},{"key":"e_1_2_8_113_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4285"},{"key":"e_1_2_8_114_2","first-page":"5078","article-title":"HER\u20102\u2010targeted therapy: lessons learned and future directions","volume":"9","author":"Nahta R","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.03.020"},{"key":"e_1_2_8_116_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903373343"},{"key":"e_1_2_8_117_2","first-page":"4132","article-title":"Herceptin\u2010induced inhibition of phosphatidylinositol\u20103 kinase and Akt Is required for antibody\u2010mediated effects on p27, cyclin D1, and antitumor action","volume":"62","author":"Yakes FM","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_8_118_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202319"},{"key":"e_1_2_8_119_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.9.3210-3223.2000"},{"key":"e_1_2_8_120_2","first-page":"260","article-title":"Anti\u2010HER2 antibody and heregulin suppress growth of HER2\u2010overexpressing human breast cancer cells through different mechanisms","volume":"6","author":"Le XF","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_8_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203470"},{"key":"e_1_2_8_122_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20378"},{"key":"e_1_2_8_123_2","first-page":"1523","article-title":"Neutralizing antibodies against epidermal growth factor and ErbB\u20102\/neu receptor tyrosine kinases down\u2010regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors","volume":"151","author":"Petit AM","year":"1997","journal-title":"Am J Pathol"},{"key":"e_1_2_8_124_2","doi-asserted-by":"publisher","DOI":"10.1038\/416279b"},{"key":"e_1_2_8_125_2","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti\u2010Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina MA","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_8_126_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"e_1_2_8_127_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.719"},{"key":"e_1_2_8_128_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0142"},{"key":"e_1_2_8_129_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.24.1852"},{"key":"e_1_2_8_130_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3900"},{"key":"e_1_2_8_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11445"},{"key":"e_1_2_8_132_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3841"},{"issue":"1","key":"e_1_2_8_133_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20040825","article-title":"PTEN function: how normal cells control it and tumour cells lose it","volume":"382","author":"Leslie NR","year":"2004","journal-title":"Biochem J"},{"key":"e_1_2_8_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.06.022"},{"key":"e_1_2_8_135_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.7.4699"},{"key":"e_1_2_8_136_2","doi-asserted-by":"publisher","DOI":"10.1159\/000279388"},{"key":"e_1_2_8_137_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M607958200"},{"key":"e_1_2_8_138_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0506"},{"key":"e_1_2_8_139_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1887"},{"key":"e_1_2_8_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.01.014"},{"key":"e_1_2_8_141_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.7116"}],"container-title":["Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20220","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsj.20220","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/msj.20220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:11:16Z","timestamp":1740719476000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/msj.20220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":140,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["10.1002\/msj.20220"],"URL":"https:\/\/doi.org\/10.1002\/msj.20220","archive":["Portico"],"relation":{},"ISSN":["0027-2507","1931-7581"],"issn-type":[{"value":"0027-2507","type":"print"},{"value":"1931-7581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}